HIMS Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -19.69%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Moderna, Inc.'s return on equity of -30.18%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 10.85%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 40.36%. Given that Moderna, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Moderna, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Moderna, Inc.'s net income of -$200M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 73.99x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.49x versus 4.42x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 21.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Pfizer Inc.'s return on equity of 10.84%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 10.85%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Pfizer Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Pfizer Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 73.99x while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.49x versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of -3135.32%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 10.85%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.33 which suggests that it could grow by 28.73%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Hims & Hers Health, Inc., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Hims & Hers Health, Inc..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Hims & Hers Health, Inc.'s net income of $15.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 73.99x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.49x versus 45.13x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 2.63% compared to Hims & Hers Health, Inc.'s net margin of 34.76%. Hims & Hers Health, Inc.'s return on equity of 25.63% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Hims & Hers Health, Inc. has a consensus price target of $44.36, signalling upside risk potential of 10.85%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $485.36 which suggests that it could grow by 4.8%. Given that Hims & Hers Health, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Hims & Hers Health, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Hims & Hers Health, Inc. has a beta of 2.414, which suggesting that the stock is 141.424% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Hims & Hers Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Hims & Hers Health, Inc. quarterly revenues are $599M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Hims & Hers Health, Inc.'s net income of $15.8M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Hims & Hers Health, Inc.'s price-to-earnings ratio is 73.99x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health, Inc. is 4.49x versus 10.23x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.